Injection twice a year! Roche B cell therapy Ocrevus treats multiple sclerosis: significantly effective in a wide range of patients!

September 12, 2020 // -- Roche recently unveiled the multiple sclerosis drug Ocrevus at the 8th ACTRIMS-ECTRIMS Joint Conference MSVirtual2020 New data from ocrelizumab show that Ocrevus is an efficient treatment option in patients with relapsed-remission multiple sclerosis (RRMS) who have not responded well to previous disease modification therapy (DMT).
subgroup analysis from the 2-year Open Label IIIb PHASECASTING study also showed that a wide range of disease-related and population subgroup patients benefited from Ocrevus therapy regardless of previous background treatment.
Dr. Levi Garraway, chief medical officer and head of global product development at Roche, said, "For a range of patients with multiple sclerosis who have not responded well to previous treatments, we continue to see evidence that Ocrevus has significant benefits in slowing disease progression.
new real-world Ocrevus data shows that patients are highly persistent and relevant to the only Twice-yearly B-cell therapy, which is important for MS patients and their doctors.
"Ocrevus was the first in the world to be approved in the United States in March 2017 and has so far been approved in 90 countries worldwide, making it the first and only drug to be approved for the treatment of RMS (including relapsed-remissive MS (RRMS), active or relapsed secondary progressive MS (SPMS), Clinical Isolation Syndrome (U.S. Market) and primary progressive multiple sclerosis (PPMS).
Ocrevus is intravenously administered every 6 months and only needs to be infused twice a year, significantly improving patient compliance.
real-world experience of Ocrevus is growing rapidly, with more than 170,000 patients worldwide receiving the drug.
multiple sclerosis (MS) is a chronic inflammatory, demyelinated central nervous system disease that affects about 2.3 million people worldwide and there is currently no cure for the disease.
MS occurs because the body's immune system abnormally attacks the brain, spinal cord, optic nerve nerve insulation and supporting structure - myelin, causing inflammation and related damage.
can cause a range of symptoms, including visual impairment, muscle weakness, difficulty speaking, severe fatigue, cognitive impairment, etc., which can lead to movement disorders and disabilities.
age of multiple sclerosis is generally between 20 and 40 years old, which is the main cause of trauma and disability in the group of young adults.
Ocrevus is an anthoclonated monoclonal antibody that selectively targets CD20-positive B cells, a specific type of immune cell that is considered a key factor in myelin and axon damage that can cause disability in patients with multiple sclerosis (MS).
preclinical studies have confirmed that Ocrevus selectively binds CD20 cell surface proteins expressed in specific B cells, but does not bind to CD20 proteins on stem cells and plasma cell surfaces, thus preserving important functions of the immune system.
data released at this meeting were as follows: (1) In the main analysis of the CASTING study, about 75% of RRMS patients (492/658) showed no signs of disease activity (NEDA; brain injury, recurrence and disability deterioration) for 2 years after switching to Ocrevus treatment twice a year (pre-specified MRI reblinization at 8 weeks).
who were included in the study were previously treated with too many to two forms of DMT therapy for at least 6 months but did not respond well.
analysis also showed that the proportion of patients who reached NEDA remained high across all the subgroups of patients measured, including baseline MRI activity, recurrence activity, disability, age, and past DMT count.
addition, 78 percent of patients treated with only one type of DMT received NEDA, while 70 percent of patients treated with two types of DMT received NEDA.
, patients treated with Ocrevus were found to have improved most of their symptoms after 2 years through symptom screening.
screening is a patient-reported outcome tool for assessing the severity of symptoms in 12 areas.
most significant improvement in physical activity is in sensory symptoms, fatigue, and vision, which are important in everyday life.
(2) CONFIDENCE Real-World Safety Study In the ongoing CONFIDENCE study in Germany, an interim analysis of more than 1,600 patients showed that at 18 months the patient's adherence to Ocrevus was 97% and the infusion was highly dependent.
, independent data from the U.S. Business Claims Database supports the high persistence and compliance of Ocrevus treatment.
(3) OCREVUS long-term safety data as of January 2020, representing 5,680 RMS and PPMS patients and Ocrevus up to 18218 patients with annual exposure.
these findings provide further evidence of Ocrevus' continued positive benefits - risk conditions - over a seven-year lyn.
() Original origin: New data further Roche's OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis.